AstraZeneca's (AZN) Overweight Rating Reiterated at JPMorgan Chase & Co.

AstraZeneca (LON:AZN - Get Free Report)'s stock had its "overweight" rating reiterated by analysts at JPMorgan Chase & Co. in a research report issued to clients and investors on Wednesday, Marketbeat Ratings reports.

A number of other equities analysts have also weighed in on the stock. Berenberg Bank reissued a "buy" rating and issued a GBX 140 ($1.77) price objective on shares of AstraZeneca in a research report on Monday, January 27th. Shore Capital reissued a "buy" rating on shares of AstraZeneca in a research report on Thursday, November 7th. Two research analysts have rated the stock with a hold rating and five have given a buy rating to the company's stock. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of GBX 7,542.80 ($95.30).

AstraZeneca Price Performance

AZN traded up GBX 118 ($1.49) during midday trading on Wednesday, reaching £117.08 ($147.92). 2,754,515 shares of the company's stock were exchanged, compared to its average volume of 25,206,791. The company has a debt-to-equity ratio of 73.83, a current ratio of 0.93 and a quick ratio of 0.59. The stock has a market capitalization of £225.27 billion, a PE ratio of 32.09, a P/E/G ratio of 0.86 and a beta of 0.17. The business's 50-day moving average price is £109.99 and its 200 day moving average price is £114.61. AstraZeneca has a 1-year low of GBX 9,670 ($122.17) and a 1-year high of £133.88 ($169.15).

About AstraZeneca

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.